This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline
Timeframe: Baseline up to Day 10
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Baseline up to 28 days after last study drug administration.
Number of Participants With Laboratory Abnormalities Meeting the Criteria for Potential Clinical Concern
Timeframe: Baseline up to Day 10
Number of Participants With Potentially Clinically Significant Vital Signs Findings
Timeframe: Baseline up to Day 10
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
Timeframe: Baseline up to Day 10
Number of Participants With Abnormal Physical Examination Findings
Timeframe: Baseline up to Day 10
Number of Participants With Abnormal Neurological Examination Findings
Timeframe: Baseline up to Day 10